Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $258,300.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at $945,842.94. This trade represents a 21.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Sandra Calvin also recently made the following trade(s):

• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Stock Down 2.8 %

Shares of TVTX opened at $17.28 on Monday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $20.33. The stock has a fifty day simple moving average of $18.11 and a two-hundred day simple moving average of $13.39. The company has a market capitalization of $1.35 billion, a PE ratio of -3.80 and a beta of 0.69.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.01. The firm had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.17) EPS. As a group, equities analysts forecast that Travere Therapeutics, Inc. will post -3.94 EPS for the current year.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently made changes to their positions in TVTX. Aigen Investment Management LP acquired a new position in shares of Travere Therapeutics during the third quarter worth about $170,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Travere Therapeutics in the third quarter valued at about $673,000. Acadian Asset Management LLC increased its position in Travere Therapeutics by 202.6% during the 2nd quarter. Acadian Asset Management LLC now owns 144,901 shares of the company’s stock worth $1,190,000 after purchasing an additional 97,020 shares during the period. Millennium Management LLC grew its holdings in Travere Therapeutics by 33.9% during the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after acquiring an additional 747,406 shares during the period. Finally, FMR LLC increased its holdings in shares of Travere Therapeutics by 27.5% in the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock valued at $2,062,000 after purchasing an additional 31,772 shares in the last quarter.

Analyst Ratings Changes

TVTX has been the topic of several recent research reports. Canaccord Genuity Group dropped their price objective on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, September 30th. Leerink Partners reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Travere Therapeutics in a research note on Tuesday, October 8th. HC Wainwright decreased their target price on shares of Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, September 27th. Barclays raised their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.67.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.